The abstract is read at the publisher; the summary is JClub's.
Beta-blocker trial participants in BETAMI-DANBLOCK had lower 3-year absolute risk of all-cause mortality or MI (7.7%–7.8%) than Norway’s NORMI revascularized MI cohort (12.0%).
- Why it matters: It is unclear how well BETAMI-DANBLOCK reflects outcomes in routine Norwegian practice for revascularized MI patients with no heart failure and LVEF ≥ 40%.
- What they did: BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with NORMI (n = 20 804), and representativeness was tested using a transportability weighting of trial participants to NORMI characteristics.
- The result: Although NORMI showed higher diabetes, prior coronary disease, and more LVEF 40–49%, beta-blocker treatment effects were similar after weighting, supporting consistent effects across these populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.